Health AI pilots often lead with a success metric: faster documentation, higher engagement, fewer clicks, or a strong model score. Those measures are incomplete unless the pilot also defines unacceptable behavior and what happens when it occurs.
Failure criteria turn principles into operating decisions. Before launch, a team should know which outputs require correction, which events require escalation, and what conditions pause or stop the pilot.
Accuracy is not one number
A system can perform well on an average benchmark and still fail in a subgroup, omit a source, misstate uncertainty, or produce an output users misunderstand. Evaluation needs measures tied to intended use and the consequences of error.
The FDA’s 2025 draft guidance for AI-enabled device software emphasizes lifecycle risk management and monitoring for changes in performance.[1] A general-wellness information system is not automatically a medical device, but the discipline of intended use, traceability, and ongoing evaluation remains valuable.
Define the boundaries before the demonstration
A pilot should state the user, inputs, output, prohibited uses, reviewer, and foreseeable misuse. For an information-organizing product, evaluation should focus on faithfulness, source identity, completeness, dates, correction, and whether the summary supports communication without implying diagnosis.
The U.S. Food and Drug Administration’s general-wellness guidance distinguishes low-risk wellness functions from functions intended for diagnosis, screening, monitoring, alerting, or disease management.[2] Product copy and interface behavior must stay consistent with the actual intended use.
Examples of failure criteria
A pilot might fail if a summary invents a source, changes a medication name, omits a correction, hides conflicting evidence, presents inference as fact, exposes protected information, or encourages emergency delay. Other criteria may address subgroup performance, accessibility, correction time, or user overreading.
A stop rule is not an admission that innovation failed. It is evidence that the organization planned for learning rather than assuming every deployment would be safe.
The RTH takeaway
A credible health AI pilot needs a claim boundary, evidence plan, human-review model, error taxonomy, escalation path, and stop conditions. SuperstarIQ is positioned as a consumer-directed general-wellness planning, information-organization, and communication-support system in development and validation. Its public-facing Source-Linked Evidence Summary should be evaluated for traceability and faithful organization—not promoted as diagnosis, prediction, prevention, or clinical clearance.
Educational note
This article provides general education and does not provide medical advice, diagnosis, or treatment. Call 911 for a medical emergency and consult a qualified professional about personal symptoms, diagnoses, medication, or care decisions.
Explore more
SuperstarIQ | Research and Evidence
Sources and further reading
- U.S. Food and Drug Administration. Artificial Intelligence Enabled Device Software Functions Lifecycle Management and Marketing Submission Recommendations. 2025 draft.
- U.S. Food and Drug Administration. General Wellness Policy for Low Risk Devices. 2026.
- National Institute of Standards and Technology. Artificial Intelligence Risk Management Framework Generative AI Profile. 2024.
Published September 15, 2026 · Last reviewed September 15, 2026